[Frequency of the Pro 12Ala polymorphism of PPARgamma2 gene in Ukrainian population and its possible role in development of metabolic syndrome].

Frequency of the Pro 12Ala gene polymorphism PPARg2 has been studied in 39 healthy men and 42 men with metabolic syndrome (MS) of the age of 40-65 years in Ukrainian population. The frequencies were 27.9% for 12Ala allele, 32.6% for Pro12Ala, and 4.4% for Ala1Ala that is close to the results of estimation of Czech population. The frequency of 12Ala allele was significantly less--18.4% (p < 0.05) in the persons with MS that corresponds to the pre-established information concerning the patients with diabetes of the 2nd type. A tendency has been detected to the increase of the body mass index in patients with 12Ala allele in the metabolic syndrome group.

[Metabolic syndrome in men of 35-65 years old from rural district of Poltava region and possibility of the prophylactic therapy with atorvastatine].

Observation of 250 men aged 35-65 years (middle age was 52 +/- 2 years) showed that prevalence of MS was 27%. Atorvastatine administration at dose of 10-20 mg per day for patients with ischemic heart disease and chronic obstructive lung disease associated with MS reduced during month administration the level of cholesterol, triglycerides, beta- and pre-beta-lipoproteids and increased the level of alpha-cholesterol in blood of these patients. Addition of atorvastatine to a common treatment patients with chronic obstructive lung disease improved as well the clinical picture of systemic inflammation process.